We are Cyclotrisiloxane, 2,4,6-triethenyl-2,4,6-trimethyl- CAS:3901-77-7 manufacturer and supplier in China, Pls send inquiry of to email@example.com of visit www.nbinno.com our official website should you have any interests
Chemical Name:Cyclotrisiloxane, 2,4,6-triethenyl-2,4,6-trimethyl-
Synonyms:Methylvinylsiloxane cyclic trimer;
2,4,6-triethenyl-2,4,6-trimethyl-cyclotrisiloxane; Cyclosiloxanes,Me vinyl;
Physical and Chemical Properties:
Index of Refraction:1.448;
Appearance:Colorless or yellowish transparent liquid
Packing:190 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:It is a very unique silicone raw material useful in the synthesis or manufacturing of reactive silioxane polymers with random vinyl functionality the backone of the silicone polymer chain.
It may be used in formulating addition-curing silicone RTV or rubber formulations.
It is a very effective inhibitor for a platinum catalyzed addition-curing Two-Part RTV. When used as an inhibitor.
It is normally added to the crosslinker part of the formulation. Its high boiling point and low evaporation rate provides an extremely stable working time at ambient temperatures of the formulated Two-Part RTV.
Related News: “This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen our diabetes portfolio but also help consolidate our position as the fastest-growing player in the anti-diabetes segment,” Mankind Pharma Director of Marketing Sanjay Koul said in a statement.L-Alanine CAS:56-41-7 Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body.13438-50-1 Taking Teva as an example, it has 2 large R & D centers and 3 professional R & D centers in 5 countries, which effectively supports the development of Teva’s generic pharmaceutical sector.L-histidina CAS:71-00-1 Zhejiang Tianyu Co., Ltd .: It is mainly engaged in the research and development and production of sartan-type APIs and intermediates. It has serialized sartan-type APIs and intermediate products, and has accumulated rich chemical synthesis technology. It has strong technical advantages and Scale advantage.The acquired pharmaceutical intermediates business will be renamed Corden Pharma Switzerland LLC and will operate as part of ICIG’s pharmaceutical business within the Corden Pharma platform. The companies’ goal is to close the transaction during the first quarter of 2011. Financial terms are not disclosed.